Literature DB >> 12661993

Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis.

M W Ziegenhagen1, M E Rothe, M Schlaak, J Müller-Quernheim.   

Abstract

The aim of the present study was to determine which bronchoalveolar lavage fluid (BALF) and serological parameters reflect the severity of newly diagnosed pulmonary sarcoidosis. Seventy-four previously untreated sarcoid patients were categorised into three groups: 10 patients with Löfgren's syndrome, 51 patients with stable disease and 13 patients with progressing disease requiring systemic steroid treatment. Total BALF cell count, percentage of alveolar lymphocytes and lymphocyte CD4/ CD8 ratio were not associated with severity of disease. Interestingly, a significant increase in percentages of BALF neutrophils (5.2 +/- 1.1%) and eosinophils (1.7 +/- 0.6%) was observed in sarcoid patients with progressing disease. Elevated percentages of these two cell types were the only BALF parameters associated with a more frequent necessity for systemic steroid therapy. This association between an elevated percentage of BALF neutrophils and the necessity for steroid treatment was observed in advanced as well as early sarcoidosis (radiological types I and II). Serum levels of soluble interleukin-2 receptor and neopterin were significantly elevated in progressing disease compared to stable disease or Löfgren's syndrome. The present results demonstrate that increased percentages of neutrophils (>3.0%) and eosinophils (>1%) in bronchoalveolar lavage fluid from newly diagnosed pulmonary sarcoidosis is associated with a significantly higher risk of necessity for steroid therapy and may be helpful markers of progressive disease. Furthermore, of the serological parameters investigated, only serum levels of soluble interleukin-2 receptor and neopterin were associated with disease severity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12661993     DOI: 10.1183/09031936.03.00010403

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  48 in total

Review 1.  A concise review of pulmonary sarcoidosis.

Authors:  Robert P Baughman; Daniel A Culver; Marc A Judson
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

Review 2.  Neurosarcoidosis.

Authors:  Dakshinamurty Gullapalli; Lawrence H Phillips
Journal:  Curr Neurol Neurosci Rep       Date:  2004-11       Impact factor: 5.081

Review 3.  Practical issues and challenges in the diagnosis and treatment of pulmonary sarcoidosis.

Authors:  Surinder K Jindal
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  The clinical value of serum soluble interleukin-2 receptor in pulmonary sarcoidosis.

Authors:  Saiko Ogata-Suetsugu; Naoki Hamada; Koichi Takayama; Kazuya Tsubouchi; Masako Arimura-Omori; Yoichi Nakanishi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

5.  Levels of transferrin in bronchoalveolar lavage fluid in sarcoidosis.

Authors:  Masahiko Shigemura; Yasuyuki Nasuhara; Satoshi Konno; Takeshi Hattori; Chikara Shimizu; Kazuhiko Matsuno; Masaharu Nishimura
Journal:  Lung       Date:  2010-04       Impact factor: 2.584

6.  (18)F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis.

Authors:  Ruth G Keijsers; Jan C Grutters; Heleen van Velzen-Blad; Jules M van den Bosch; Wim J Oyen; Fred J Verzijlbergen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-16       Impact factor: 9.236

7.  Risk factors of relapse in pulmonary sarcoidosis treated with corticosteroids.

Authors:  Yi Zheng; Hui Wang; Qingqing Xu; Xin Yan; Yi Zhuang; Hanyi Jiang; Fanqing Meng; Yonglong Xiao; Hourong Cai; Jinghong Dai
Journal:  Clin Rheumatol       Date:  2019-03-15       Impact factor: 2.980

8.  Interleukin-15 increases neutrophil adhesion onto human respiratory epithelial A549 cells and attracts neutrophils in vivo.

Authors:  M Pelletier; D Girard
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

9.  Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease.

Authors:  E Fortunati; K M Kazemier; J C Grutters; L Koenderman; van J M M Van den Bosch
Journal:  Clin Exp Immunol       Date:  2008-12-09       Impact factor: 4.330

10.  BAL fluid cells in newly diagnosed pulmonary sarcoidosis with different clinical activity.

Authors:  Edvardas Danila; Laimute Jurgauskiene; Jolita Norkuniene; Radvile Malickaite
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.